(Q31522100)

2 July 2017

1 reference

title

Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development (English)

1 reference

2 July 2017

0 references

0 references

1 reference

Pertwee RG

1

1 reference

PubMed ID

11060760

2 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

Expert Opinion on Investigational Drugs

2 July 2017

1 reference

2 July 2017

9

1 reference

2 July 2017

1553-1571

1 reference

2 July 2017

7

1 reference

Pharmacology of cannabinoid CB1 and CB2 receptors.

2 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Control of pain initiation by endogenous cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Cannabinoids control spasticity and tremor in a multiple sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

An investigation into the structural determinants of cannabinoid receptor ligand efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Structural determinants for recognition and translocation by the anandamide transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Structure-activity relationships of anandamide, an endogenous cannabinoid ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Biochemistry of the endogenous ligands of cannabinoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Mesenteric vasodilation mediated by endothelial anandamide receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Interactions between synthetic vanilloids and the endogenous cannabinoid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Anandamide transport inhibition by the vanilloid agonist olvanil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Neuropharmacology and therapeutic potential of cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Cannabinoid transmission and pain perception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Effective treatment of Tourette's syndrome with marijuana.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

The perceived effects of smoked cannabis on patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

(+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Analgesic Effect of Delta‐9‐Tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Nabilone in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Two distinctive antinociceptive systems in rats with pathological pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Antihyperalgesic effects of spinal cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Pain relief with oral cannabinoids in familial Mediterranean fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Pain modulation by release of the endogenous cannabinoid anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1553

10.1517/13543784.9.7.1553

21 January 2018

Identifiers

DOI

1 reference

2 July 2017

1 reference

PubMed ID

11060760